Both in Surgical Instruments
Cerus vs Neuropace
Over the past year CERS returned +50.3% and NPCE returned +32.6%; their daily moves had a correlation of 0.28.
CERS +50.3% NPCE +32.6%Growth of $1, one year, split-adjusted
| Metric | CERS | NPCE |
|---|---|---|
| Price | $2.29 | $12.46 |
| Market cap | $460.5M | $427.7M |
| Today | −3.18% | +0.97% |
| 1 month | −2.4% | −5.7% |
| 6 months | −11.8% | −26.9% |
| Year to date | +10.9% | −19.3% |
| 1 year | +55.4% | +25.4% |
| Revenue growth (YoY) | +6.3% | +17.1% |
| Gross margin | 57.1% | 82.8% |
| Net margin | −0.9% | −27.2% |
| P/E (TTM) | — | — |
| Price / sales | 1.8× | 4.3× |
| Net cash | -$6.2M | -$7.3M |
| Dividend yield | — | — |
| Volatility (60d) | 44.8% | 40.2% |
| Short % of float | 8.6% | 3.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).